Ocular Therapeutix™ to Announce Topline Data for SOL-1 Phase 3 Superiority Trial in Wet AMD on Tuesday, February 17, 2026

Rhea-AI Summary

Ocular Therapeutix (NASDAQ: OCUL) will host a webcast on Tuesday, February 17, 2026 at 8:00 AM ET to review topline results from the SOL-1 Phase 3 superiority trial of AXPAXLI (OTX-TKI) for wet age-related macular degeneration.

Detailed SOL-1 data will be presented at the 49th Macula Society Annual Meeting from February 25–28, 2026. The live webcast and archived replay (available for at least 30 days) can be accessed via the company's Investor Relations Events and Presentations page.

Market Reaction

+25.11% $11.11

15m delay 18 alerts

+25.11% Since News

$11.11 Last Price

$8.83 $11.37 Day Range

+$388M Valuation Impact

$1.93B Market Cap

0.1x Rel. Volume

Following this news, OCUL has gained 25.11%, reflecting a significant positive market reaction. Our momentum scanner has triggered 18 alerts so far, indicating notable trading interest and price volatility. The stock is currently trading at $11.11. This price movement has added approximately $388M to the company's valuation.

Data tracked by StockTitan Argus (15 min delayed). Upgrade to Silver for real-time data.

Key Figures

SOL-1 topline date: February 17, 2026 Webcast time: 8:00 AM ET Macula Society meeting: 49th annual +2 more

5 metrics

SOL-1 topline date February 17, 2026 Topline data for Phase 3 SOL-1 superiority trial in wet AMD

Webcast time 8:00 AM ET Company webcast reviewing SOL-1 topline results

Macula Society meeting 49th annual Detailed SOL-1 data presentation venue

Macula meeting dates February 25–28, 2026 Conference window for detailed SOL-1 data

Webcast replay period At least 30 days Archived access to SOL-1 topline webcast

Market Reality Check

Price: $8.88 Vol: Volume 2,654,161 vs 20-da...

low vol

$8.88 Last Close

Volume Volume 2,654,161 vs 20-day average 5,875,090 ahead of the SOL-1 topline webcast date announcement. low

Technical Shares at $8.88, trading below the 200-day MA of $10.96 despite the upcoming Phase 3 SOL-1 readout timing.

Peers on Argus

OCUL was down 1.09% pre-announcement while peers were mixed: BEAM up 0.98%, TARS...

OCUL was down 1.09% pre-announcement while peers were mixed: BEAM up 0.98%, TARS down 4.81%, BLTE down 1.11%, LQDA down 2.2%, TVTX down 9.08%, suggesting stock-specific focus on its SOL-1 catalyst timeline rather than a broad biotech move.

Previous Clinical trial Reports

5 past events · Latest: Dec 08 (Positive)

Same Type Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Dec 08	NDA timing update	Positive	+28.1%	Planned accelerated NDA submission for AXPAXLI after positive SOL-1 topline data.
Nov 24	Phase 3 enrollment	Positive	-1.1%	First patient randomized in HELIOS-3 Phase 3 NPDR trial with novel DRSS endpoint.
Sep 30	Investor Day trials	Positive	-6.7%	Investor Day detailing SOL-1 and SOL-R progress and new HELIOS Phase 3 plans.
Apr 18	Phase 1 topline	Positive	-22.7%	Positive topline Phase 1 data for AXPAXLI in diabetic retinopathy.
Feb 13	Phase 3 start	Positive	-4.4%	First subjects screened in Phase 3 pivotal AXPAXLI trial in wet AMD.

Pattern Detected

Clinical trial communications have often seen negative or muted next-day moves, even when describing constructive AXPAXLI progress.

Recent Company History

Over the past two years, OCUL has repeatedly highlighted AXPAXLI’s advancement across multiple Phase 3 programs. Prior clinical updates included plans to accelerate an NDA in wet AMD based on SOL-1, initiation of HELIOS-3 in NPDR, and strong SOL program retention. Yet same-tag news often produced negative next-day moves, with four of five clinical trial events showing declines despite constructive trial or program updates. Today’s announcement fits into this sequence as it locks in the date and venue for SOL-1 Phase 3 topline disclosure.

Historical Comparison

-1.4% avg move · Clinical-trial-tagged headlines for OCUL have averaged a -1.38% next-day move, even when describing ...

clinical trial

-1.4%

Average Historical Move clinical trial

Clinical-trial-tagged headlines for OCUL have averaged a -1.38% next-day move, even when describing constructive AXPAXLI progress, so the SOL-1 topline-date notice fits a catalyst-heavy but volatile news pattern.

Clinical-trial news shows a clear AXPAXLI progression: from first subjects screened in wet AMD, to positive Phase 1 diabetic retinopathy data, to SOL program Investor Day updates, then HELIOS NPDR Phase 3 enrollment and plans to accelerate a wet AMD NDA off SOL-1 topline.

Regulatory & Risk Context

Active S-3 Shelf

Shelf Active

Active S-3 Shelf Registration 2025-09-30

An effective Form S-3ASR shelf, filed 2025-09-30, allows OCUL to periodically issue various securities, including debt, common and preferred stock, depositary shares, warrants, and units for general corporate purposes such as R&D, clinical trials, regulatory submissions, commercialization, manufacturing, acquisitions, debt repayment, and working capital.

Market Pulse Summary

The stock is surging +25.1% following this news. A strong positive reaction aligns with the stock’s ...

Analysis

The stock is surging +25.1% following this news. A strong positive reaction aligns with the stock’s catalyst-rich backdrop, as SOL-1 represents a pivotal Phase 3 superiority trial in wet AMD with topline data scheduled for February 17, 2026. Historical clinical-trial headlines have averaged a -1.38% move, so outsized strength could mark a break from past skepticism. Investors would still need to weigh future financing flexibility under the existing S-3ASR and the potential for sentiment shifts once detailed Macula Society data emerge.

Key Terms

phase 3, wet age-related macular degeneration, wet amd, webcast

4 terms

phase 3 medical

"topline results of the SOL-1 Phase 3 superiority clinical trial of AXPAXLI"

Phase 3 is the late-stage clinical testing step for a new drug or medical treatment, where the product is given to large groups of patients to confirm effectiveness, monitor side effects, and compare it to standard care. Successful Phase 3 results are often the final scientific hurdle before regulators decide on approval and market launch—like passing a final exam before graduation—and can sharply change a company's valuation and future revenue prospects.

wet age-related macular degeneration medical

"for the treatment of wet age-related macular degeneration (wet AMD)"

A severe eye condition in which abnormal, fragile blood vessels grow beneath the macula — the small central part of the retina responsible for sharp, detailed vision — and leak fluid or blood, causing rapid loss of central sight. Investors care because the condition drives demand for high-cost therapies, medical devices and ongoing care; successful treatments can create sizable markets, affect healthcare spending and influence regulatory and reimbursement decisions, much like fixing a leaking camera lens restores image quality and value.

wet amd medical

"for the treatment of wet age-related macular degeneration (wet AMD)"

Wet AMD (wet age-related macular degeneration) is an eye disease in older adults where abnormal, leaky blood vessels grow under the retina and cause rapid vision loss in the center of the visual field. It matters to investors because it creates a sustained market for treatments, diagnostics and devices: changes in diagnosis rates, new drugs, or reimbursement rules can quickly affect healthcare revenues and the valuation of companies working on therapies.

webcast technical

"Company will host a webcast to review the topline results"

A webcast is a live or recorded online event where people watch or listen to presentations, announcements, or performances through the internet. It’s like a TV broadcast but over the internet, allowing viewers from anywhere to tune in in real time or later. Webcasts are important because they let companies share information quickly and widely with audiences around the world.

AI-generated analysis. Not financial advice.

Ocular to host webcast scheduled for Tuesday, February 17, 2026, at 8:00 AM ET

Detailed SOL-1 data to be presented at the 49^th Macula Society Annual Meeting

BEDFORD, Mass., Feb. 13, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that the Company will host a webcast to review the topline results of the SOL-1 Phase 3 superiority clinical trial of AXPAXLI™ (also known as OTX-TKI), for the treatment of wet age-related macular degeneration (wet AMD), on Tuesday, February 17, 2026. Detailed data will be presented at the 49^th Macula Society Annual Meeting between February 25 – 28, 2026.

Click here to register for the virtual webcast, which will begin at 8:00 AM ET.

The live and archived webcast can also be accessed by visiting the Ocular Therapeutix website on the Events and Presentations section of the Investor Relations page. A replay of the webcast will be archived for at least 30 days.

About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. is an integrated biopharmaceutical company committed to redefining the retina experience. AXPAXLI™ (also known as OTX-TKI), Ocular’s investigational product candidate for retinal disease, is an axitinib intravitreal hydrogel based on its ELUTYX™ proprietary bioresorbable hydrogel-based formulation technology. AXPAXLI is currently in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD) and diabetic retinal disease, including non-proliferative diabetic retinopathy (NPDR).

Ocular’s pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA^®, an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery in adults and pediatric patients and ocular itching associated with allergic conjunctivitis in adults and pediatric patients aged two years or older, and in its investigational product candidate OTX-TIC, which is a travoprost intracameral hydrogel that has completed a Phase 2 clinical trial for the treatment of open-angle glaucoma or ocular hypertension. Ocular is currently evaluating next steps for the OTX-TIC program.

Follow the Company on its website, LinkedIn, or X.

DEXTENZA^® is a registered trademark of Ocular Therapeutix, Inc. The Ocular Therapeutix logo, AXPAXLI™, ELUTYX™, and Ocular Therapeutix™ are trademarks of Ocular Therapeutix, Inc.

Investors & Media
Ocular Therapeutix, Inc.
Bill Slattery
Vice President, Investor Relations
bslattery@ocutx.com

FAQ

When will Ocular Therapeutix (OCUL) release SOL-1 Phase 3 topline results?

The company will review SOL-1 topline results on February 17, 2026 at 8:00 AM ET. According to the company, a live webcast will cover the topline findings and a replay will be archived for at least 30 days.

Where will Ocular Therapeutix (OCUL) present detailed SOL-1 data in February 2026?

Detailed SOL-1 data will be presented at the 49th Macula Society Annual Meeting from February 25–28, 2026. According to the company, the full dataset will be shared during that meeting for clinical review.

How can investors access the OCUL webcast for SOL-1 topline results on February 17, 2026?

Investors can access the live webcast via the company's Investor Relations Events and Presentations page. According to the company, registration is available and an archived replay will be posted for at least 30 days.

What is AXPAXLI (OTX-TKI) and why is the SOL-1 result important for OCUL investors?

AXPAXLI (OTX-TKI) is the SOL-1 Phase 3 study drug for treating wet AMD; topline results indicate trial direction. According to the company, the webcast will summarize primary outcomes ahead of detailed meeting presentation.

Will the OCUL webcast on February 17, 2026 include detailed clinical data or just topline results?

The webcast will review the SOL-1 topline results on February 17, 2026; detailed data will follow. According to the company, full data are scheduled for presentation at the Macula Society meeting February 25–28, 2026.